In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...
The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback